Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Amydis secures funding for retinal Parkinsonís test
September 2018
SHARING OPTIONS:

SAN DIEGO—Amydis Inc. received a grant in the third quarter of 2018 from The Michael J. Fox Foundation for Parkinson’s Research to support research into using Amydis' platform technology to engineer an ophthalmic test that could identify patients at risk of Parkinson’s disease. At present, early-stage diagnosis is difficult; Amydis' approach will focus on the detection of alpha-synuclein as a biomarker.
 
“Parkinson’s disease represents a major public health issue. Clinically meaningful interventional research has to date been hampered by the lack of early diagnostic capacity,” said Dr. Steven Schwartz, Ahmanson Professor in Ophthalmology and chief, Retina Division at the Jules Stein Eye Institute, David Geffen School of Medicine at UCLA. “Lack of a validated biomarker and inability to make reliable, early diagnosis has greatly slowed clinical research. As such, the Amydis test addresses a highly impactful barrier in the race towards meaningful intervention.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.